How Analysts Rated Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Last Week?

May 16, 2018 - By Jan Rainey

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) LogoInvestors sentiment decreased to 1.34 in Q4 2017. Its down 0.28, from 1.62 in 2017Q3. It fall, as 53 investors sold Vertex Pharmaceuticals Incorporated shares while 160 reduced holdings. 72 funds opened positions while 213 raised stakes. 232.48 million shares or 0.46% more from 231.42 million shares in 2017Q3 were reported.
Bowen Hanes Comm invested in 165,000 shares. Manufacturers Life Insur Communications The reported 313,381 shares. Ameriprise accumulated 0.36% or 5.26 million shares. Suntrust Banks Incorporated invested 0.02% in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Bnp Paribas Arbitrage Sa stated it has 198,008 shares. Goldman Sachs Grp Inc has 0.12% invested in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) for 3.23 million shares. State Of Tennessee Treasury Department holds 0.12% or 186,325 shares. Fdx Advsr Incorporated holds 0.02% or 6,007 shares. Wells Fargo Co Mn reported 0.09% in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Numeric Limited Liability Corp holds 0.01% or 13,700 shares in its portfolio. Cetera Advisor Limited Co holds 0.01% or 1,766 shares. Eulav Asset holds 0.94% in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) or 133,000 shares. 1,229 are held by Baldwin Brothers Incorporated Ma. Sumitomo Mitsui Hldgs Inc holds 0.16% of its portfolio in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) for 807,388 shares. Valley Advisers Inc reported 151 shares or 0.01% of all its holdings.

Since December 11, 2017, it had 0 insider purchases, and 44 sales for $106.32 million activity. Sachdev Amit had sold 17,796 shares worth $2.68M on Monday, February 12. $3.25 million worth of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) was sold by MCGLYNN MARGARET G on Monday, January 22. Another trade for 8,500 shares valued at $1.39M was sold by Arbuckle Stuart A. Another trade for 40,764 shares valued at $6.49 million was made by Parini Michael on Wednesday, April 25. Silva Paul M sold $544,730 worth of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) on Tuesday, February 20. $287,360 worth of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) shares were sold by ALTSHULER DAVID.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Ratings Coverage

Among 18 analysts covering Vertex Pharmaceuticals (NASDAQ:VRTX), 18 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Vertex Pharmaceuticals had 25 analyst reports since December 12, 2017 according to SRatingsIntel. Morgan Stanley maintained the shares of VRTX in report on Friday, February 2 with “Overweight” rating. Credit Suisse maintained it with “Outperform” rating and $196 target in Tuesday, February 13 report. The firm has “Buy” rating given on Friday, April 27 by Oppenheimer. RBC Capital Markets maintained the shares of VRTX in report on Wednesday, January 31 with “Buy” rating. BMO Capital Markets maintained the shares of VRTX in report on Tuesday, January 2 with “Buy” rating. The stock has “Buy” rating by Guggenheim on Wednesday, January 31. The company was upgraded on Thursday, February 1 by Barclays Capital. As per Thursday, February 1, the company rating was maintained by Leerink Swann. The company was maintained on Wednesday, January 31 by Jefferies. On Thursday, February 1 the stock rating was maintained by Piper Jaffray with “Buy”. Below is a list of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) latest ratings and price target changes.

27/04/2018 Broker: Morgan Stanley Old Rating: Overweight New Rating: Overweight Old Target: $200 New Target: $207 Maintain
27/04/2018 Broker: Oppenheimer Rating: Buy New Target: $190.0000 Maintain
04/04/2018 Broker: RBC Capital Markets Rating: Buy New Target: $199.0000 Maintain
13/03/2018 Broker: Cowen & Co Rating: Buy New Target: $200.0 Maintain
05/03/2018 Broker: Maxim Group Old Rating: Buy New Rating: Buy Old Target: $195 New Target: $200 Maintain
23/02/2018 Broker: Argus Research Rating: Buy New Target: $194.0
13/02/2018 Broker: JMP Securities Old Rating: Market Outperform New Rating: Market Outperform Old Target: $200 New Target: $211 Maintain
13/02/2018 Broker: Credit Suisse Old Rating: Outperform New Rating: Outperform Old Target: $195 New Target: $196 Maintain
02/02/2018 Broker: Morgan Stanley Old Rating: Overweight New Rating: Overweight Old Target: $198 New Target: $200 Maintain
01/02/2018 Broker: Oppenheimer Rating: Buy New Target: $190.0 Upgrade

The stock increased 0.40% or $0.62 during the last trading session, reaching $156.16. About 971,857 shares traded. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) has risen 76.59% since May 16, 2017 and is uptrending. It has outperformed by 65.04% the S&P500.

Vertex Pharmaceuticals Incorporated discovers, develops, makes, and commercializes medicines for serious diseases. The company has market cap of $39.79 billion. The firm focuses on developing and commercializing therapies for the treatment of cystic fibrosis and advancing its research and development programs. It has a 150.3 P/E ratio. It markets ORKAMBI (lumacaftor in combination with ivacaftor) for the treatment of patients with CF 12 years of age and older who have two copies (homozygous) of the F508del mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene; and KALYDECO (ivacaftor) for the treatment of patients with CF 2 years of age and older who have the G551D mutation or other specified mutations in their CFTR gene.

More notable recent Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) news were published by: Globenewswire.com which released: “Factors of Influence in 2018, Key Indicators and Opportunity within American Homes 4 Rent, Discovery …” on May 10, 2018, also Fool.com with their article: “Vertex Pharmaceuticals Takes a Detour Around the FDA’s Roadblock” published on April 30, 2018, Streetinsider.com published: “Vertex Pharma (VRTX), Alexion Pharma (ALXN) Least Impacted from Trump Drug Policies – RBC” on May 15, 2018. More interesting news about Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) were released by: Fool.com and their article: “3 Top Biotech Stocks to Buy in May” published on May 09, 2018 as well as Seekingalpha.com‘s news article titled: “Vertex Pharmaceuticals Heads Toward An Important Tipping Point” with publication date: May 01, 2018.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: